Biotech
5 Early-Stage Startups Building New Tools for Drug Research
DealBio tracks early-stage health and life-science startups across Europe and North America. These 5 are building tools that can improve how drug-research teams measure, model and test biology.
- Drug Discovery
- Lab Instruments
- Tissue Engineering
- Protein Analysis
- Precision Medicine
DealBio tracks early-stage health and life-science startups across Europe and North America. These 5 are building tools that can improve how drug-research teams measure, model and test biology.
Drug research depends on the quality of the models and measurements available before a program reaches the clinic. New tools are emerging to capture biological detail that bulk measurements and simplified preclinical systems can miss.
Across this group, the shared opportunity is better decision quality earlier in R&D. The products aim to help teams characterize proteins, reproduce human tissue, compare treatment responses or prioritize signals before larger development decisions are made.
At a Glance
- UNOMRSwitzerland2025Single-molecule protein analysis
- AsemblisSwitzerland20253D human fat-tissue models
- RevoBITsGermany2026Multi-material bioprinting
- OrganAIDSpain2025Patient-derived organoid testing
- CancerTwinSweden2026Digital tumor models
01
UNOMR
Building nanopore sensors that analyze protein modifications one molecule at a time
- Country
Switzerland- Founded
- 2025
- Sector
- Biotech
- Funding stage
- Seed or earlier
Why UNOMR stands out
UNOMR is building an analytical layer for proteins around ETH Zurich-derived nanopore technology. The startup has secured CHF 300,000 in non-dilutive funding, with Nestlé testing its single-protein glycosylation readout.
The combination of single-molecule measurement and an industry application gives the platform a clear route into protein-characterization workflows.
What UNOMR is building
UNOMR uses adjustable interface nanopores to measure individual proteins and chemical modifications such as glycosylation.
The benchtop platform is being developed for pharma, biotech and medical-nutrition teams that need more detailed information about protein heterogeneity.
02
Asemblis
Building 3D human fat-tissue models for obesity drug development.
- Country
- Switzerland
- Founded
- 2025
- Sector
- Biotech
- Funding stage
- Seed or earlier
- Founders
Why Asemblis stands out
Asemblis has secured a commercial partnership with Viscofan BioEngineering and added ZHAW 3D-tissue leader Markus Rimann as a scientific adviser. CEO Caio Valeriano also brings bioprinting commercialization experience from REGENHU.
Those signals matter in an R&D workflow where adoption depends on reproducibility and confidence that the tissue model adds information beyond standard preclinical systems.
What Asemblis is building
Asemblis builds biofabricated 3D human fat-tissue models for obesity and metabolic-disease research.
Biopharma teams can scope feasibility studies around defined questions such as inflammation, weight regain, muscle loss and safety, with endpoints agreed before the work begins.
03
RevoBITs
Building bioprinting hardware for multi-material human tissue models.
- Country
Germany- Founded
- 2026
- Sector
- Biotech
- Funding stage
- Seed or earlier
Why RevoBITs stands out
RevoBITs secured €1.25 million through EXIST Research Transfer and has moved its byte 1 system into pilots at University Hospital Würzburg and University Hospital FAU Erlangen.
The combination of multi-material printing and inline sensing is aimed at a practical research problem: producing complex tissue models reproducibly enough for laboratories to compare experiments across runs.
What RevoBITs is building
RevoBITs is building a bioprinter with a multi-material printhead, independent temperature zones and inline sensing.
The platform is designed for research groups that need to place multiple bioinks and cell types in one construct while controlling conditions during printing.
04
OrganAID
Testing drug responses in patient-derived tissue models with AI analysis.
- Country
Spain- Founded
- 2025
- Sector
- Biotech
- Funding stage
- Seed or earlier
Why OrganAID stands out
OrganAID combines patient-derived tissue models with predictive image analysis and licensed the core technology from the University of Barcelona and Pompeu Fabra University.
Its ChemoStart win adds industry-facing development support and a route into pharmaceutical research projects.
What OrganAID is building
OrganAID grows patient-derived organoids and analyzes how they respond to candidate drugs.
The workflow uses AI on static and live images to assess tissue-model quality, toxicity and treatment effects while retaining patient-specific biological variation.
Using digital tumor models to discover early cancer biomarkers.
- Country
Sweden- Founded
- 2026
- Sector
- Diagnostics
- Funding stage
- Seed or earlier
- Founders
- Mikael Benson
Why CancerTwin stands out
CancerTwin commercializes digital-twin research from Karolinska Institutet and the Swedish Digital Twin Consortium. Its scientific foundation includes biomarker work involving nearly 2,000 prostate-cancer patients.
The platform adds a computational layer to experimental research by combining clinical and multi-omics data to prioritize mechanisms and biomarkers before targeted validation.
What CancerTwin is building
CancerTwin constructs digital tumor models at group, subtype and individual levels using clinical and multi-omics information.
The models are designed to identify early disease mechanisms, biomarker candidates and potential drug targets that can then be tested in laboratory and clinical studies.
Deal Sourcing for Investors
Looking for More Startups Like These?
DealBio helps investment teams discover, research, and monitor early-stage healthcare and life sciences startups aligned with their investment criteria.
Investment perspective
These startups occupy different layers of the preclinical stack: molecular measurement, engineered human tissue, fabrication hardware, patient-derived testing and computational disease modeling. Taken together, they point to the same shift in drug research: more of the biological uncertainty is being pushed upstream, before a program reaches expensive animal studies or clinical development.
The commercial models, however, are not identical. Instruments and software can scale through standardized workflows and recurring use, while tissue-model and organoid businesses may begin with project-based services. For investors, the important signal is whether those service-heavy models become repeatable enough to generate standardized studies, recurring customers and proprietary datasets rather than remaining bespoke research work.
Methodology
DealBio selected these five early-stage startups because their products are designed to improve how drug-research teams measure, model or test biology before larger development decisions are made. The selection spans protein analysis, bioprinting, human tissue models, organoids and computational disease modeling.
DealBio builds its Startup Briefs using publicly available startup materials, ecosystem sources, market references and professional profiles.